Madrigal Pharmaceuticals, Inc , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
infoMadrigal Pharmaceuticals is a mid cap stock with a total market cap of 3.31B.
infoThey trade on the NASDAQ and had their IPO 16 years and 6 months ago.
infoMadrigal Pharmaceuticals currently employs 92 people.
infoAs of Wednesday, Aug 23 2023, Madrigal Pharmaceuticals’s share price is $179.2.
News Relating to Madrigal Pharmaceuticals
Seeking Alpha
Madrigal’s Resmetirom Nears Commercialization Despite Market Concerns
Sunday Aug 20 2023 at 10:27
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable debt, but faces rising R&D costs and competition in the NASH therapeutics field. My recommendation remains a “Buy” for risk-tolerant investors, despite concerns about weight loss drugs reducing NASH market potential.
Seeking Alpha
Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next
Thursday Jul 13 2023 at 17:30
Madrigal Pharmaceuticals, Inc. dual surrogate Primary endpoint being met in phase 3 MAESTRO-NASH study allowed for the rolling NDA submission of resmetirom for the treatment of patients with NASH. Potential for rolling NDA submission of resmetirom to be granted Priority Review Status, which would cut review time from 10 months to 6 months. The phase 3 MAESTRO-NASH-OUTCOMES study would not only grant Accelerated Approval of resmetirom to full approval, but may also allow the possibility of obtaining full approval of well-compensated NASH cirrhosis.
Market Watch
Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment
Friday Jun 30 2023 at 12:28
Madrigal Pharmaceuticals Inc.’s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of its resmetirom as a treatment for, nonalcoholic steatohepatitis, or NASH, with liver fibrosis. NASH is a more severe version of nonalcoholic fatty liver disease, or NAFLD, a range of conditions that occurs when excess fat builds up in liver cells.
Market Watch
Weight-loss drugs in development aim to replace injections with pills
Monday Jun 26 2023 at 15:21
Wall Street’s obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.
The Motley Fool
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Tuesday May 30 2023 at 05:38
Two stocks in the healthcare sector have already doubled this year, and they could climb much higher, according to Wall Street. Viking Therapeutics is a clinical-stage biotech with an experimental treatment that could treat millions of underserved liver disease patients.
Seeking Alpha
Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
Tuesday May 30 2023 at 01:19
Madrigal Pharmaceuticals’ drug, resmetirom, for non-alcoholic fatty liver diseases, received FDA’s Breakthrough Therapy designation. The company is now focused on the MAESTRO-NASH-OUTCOMES trial. Madrigal’s Q1 2023 financial reports show a decrease in cash holdings, and an increase in operating and R&D costs due to Phase 3 trials and workforce expansion. Competitor Intercept Pharmaceuticals faced a setback for its NASH drug, obeticholic acid, emphasizing the FDA’s stringent safety and efficacy standards for NASH treatments.
The Motley Fool
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Wednesday May 24 2023 at 13:17
The shares are continuing a yearlong winning streak today. This latest uptick appears to be the result of two tailwinds.
The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today
Tuesday May 16 2023 at 15:42
The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape today.
The Motley Fool
Why Madrigal Pharmaceuticals Stock Is Slumping Today
Tuesday May 09 2023 at 13:54
Madrigal Pharmaceuticals stock plummeted in early-morning trading following its 2023 Q1 earnings report. Bargain hunters were quick to buy the dip, however.
The Motley Fool
3 Biotechs That Might Get Bought Out in 2023
Wednesday Apr 26 2023 at 11:30
With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors soon.
The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
Thursday Apr 20 2023 at 14:06
On Tuesday, Madrigal won an important regulatory designation from the FDA for its NASH candidate. The biotech got another boost from the ongoing buyout bonanza in biotech.
Benzinga
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Thursday Apr 20 2023 at 08:07
Where is the current bull market? All indications would be that it’s in biotech!
Zacks Investment Research
Madrigal (MDGL) Gains on NASH Treatment’s Breakthrough Therapy Tag
Wednesday Apr 19 2023 at 15:12
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
Investors Business Daily
Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
Tuesday Apr 18 2023 at 12:00
Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point. The post Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout appeared first on Investor’s Business Daily.
24/7 Wall Street
These Are the Top 10 Holdings of Avoro Capital Advisors
Monday Apr 17 2023 at 22:54
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
The Motley Fool
5 Best Stocks to Buy in April
Saturday Apr 01 2023 at 13:43
Several key themes are emerging in the stock investing landscape. These five stocks are poised to benefit from these powerful trends.
Seeking Alpha
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
Wednesday Mar 29 2023 at 23:40
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.
Investors Business Daily
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
Friday Mar 10 2023 at 12:29
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle appeared first on Investor’s Business Daily.
Investors Business Daily
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
Friday Mar 10 2023 at 11:49
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle appeared first on Investor’s Business Daily.
The Motley Fool
1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030
Thursday Mar 09 2023 at 13:56
The stock market tends to be efficient at pricing equities, but not always. Experimental drug developers in particular have often turned out to be wildly mispriced by skeptical investors.
Zacks Investment Research
This “Golden” Technical Indicator is Triggering Across the Market
Thursday Jan 26 2023 at 09:47
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
24/7 Wall Street
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
Thursday Jan 19 2023 at 22:53
Mid-cap stocks are proving to be an attractive investment option over the past few years.
Seeking Alpha
Madrigal: Fairly Valued At These Levels
Tuesday Jan 17 2023 at 14:35
As everyone knows, Madrigal outperformed expectations with outstanding results stemming from Maestro NASH study. I assess Madrigal’s current valuation, based on future sales potential of resmetirom in the US as a basis.
The Motley Fool
3 Top Healthcare Stocks to Buy for January
Wednesday Jan 11 2023 at 05:52
These healthcare stocks have a lot going for them in the new year.
24/7 Wall Street
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
Monday Jan 09 2023 at 22:50
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
CNBC
Traders who bet against stocks made a killing in 2022, as short sellers netted $300 billion
Thursday Jan 05 2023 at 20:35
Short holdings had a return of 30.8% in 2022 as the market slid.
InvestorPlace
Why These 7 Healthcare Stocks Could Soar in 2023
Monday Jan 02 2023 at 07:22
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today’s industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.
Seeking Alpha
Madrigal Pharmaceuticals Setting The Standard
Monday Dec 26 2022 at 12:36
Madrigal’s lead drug candidate was already expected to be successful in its pivotal trial. FDA approval would then be earned by a positive on one of the trial’s dual endpoints.
The Motley Fool
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
Monday Dec 26 2022 at 05:21
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company’s results.
Seeking Alpha
Madrigal Pharmaceuticals: Upcoming Windfall Profits
Friday Dec 23 2022 at 08:31
Like an early Christmas/Hanukkah present, Madrigal shares rallied over 268% in one session due to the positive MAESTRO-NASH data. The shares continue to move in the ensuing day. Coupled with the strong Phase 3 (MAESTRO-NAFLD-1) results, Madrigal is poised to file a marketing application in H1 next year.
Madrigal Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Madrigal Pharmaceuticals’s Altman Z-score is 1.97 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
Madrigal Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Madrigal Pharmaceuticals.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Madrigal Pharmaceuticals’s Income Quality of 0.54 is lower than its Industry Group of 0.69 (-21.7% lower)
Madrigal Pharmaceuticals’s Income Quality of 0.54 is lower than its Major Industry Group of 0.71 (-23.9% lower)
Madrigal Pharmaceuticals’s Income Quality of 0.54 is lower than its Sector of 0.75 (-28.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Madrigal Pharmaceuticals’s Current Ratio of 3.02 is lower than its Industry Group of 4.76 (-36.6% lower)
Madrigal Pharmaceuticals’s Current Ratio of 3.02 is lower than its Major Industry Group of 4.32 (-30.1% lower)
Madrigal Pharmaceuticals’s Current Ratio of 3.02 is greater than its Sector of 2.6 (16.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-9.91 & -1.27)
Cannot compare a negative PE Ratio (-9.91 & -1.1)
Cannot compare a negative PE Ratio (-9.91 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Madrigal Pharmaceuticals’s PB Ratio of 31.98 is greater than its Industry Group of 1.34 (2286.6% greater)
Madrigal Pharmaceuticals’s PB Ratio of 31.98 is greater than its Major Industry Group of 1.4 (2184.3% greater)
Madrigal Pharmaceuticals’s PB Ratio of 31.98 is greater than its Sector of 1.62 (1874.1% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Madrigal Pharmaceuticals’s ROE of -3.23 is lower than its Industry Group of -0.44 (-634.1% lower)
Madrigal Pharmaceuticals’s ROE of -3.23 is lower than its Major Industry Group of -0.38 (-750.0% lower)
Madrigal Pharmaceuticals’s ROE of -3.23 is lower than its Sector of -0.03 (-10666.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Madrigal Pharmaceuticals’s ROCE of -1.63 is lower than its Industry Group of -0.42 (-288.1% lower)
Madrigal Pharmaceuticals’s ROCE of -1.63 is lower than its Major Industry Group of -0.37 (-340.5% lower)
Madrigal Pharmaceuticals’s ROCE of -1.63 is lower than its Sector of -0.04 (-3975.0% lower)
Derived from SEC.GOV filing dataopen_in_new